These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32886347)

  • 1. Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation.
    Jaruratanasirikul S; Vattanavanit V; Wongpoowarak W; Nawakitrangsan M; Samaeng M
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):735-747. PubMed ID: 32886347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NONMEM population pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with or without extracorporeal membrane oxygenation in an intensive care unit.
    Jaruratanasirikul S; Boonpeng A; Nawakitrangsan M; Samaeng M
    Pharmacotherapy; 2021 Jul; 41(7):572-597. PubMed ID: 34080708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Imipenem in Critically Ill Patients with Life-threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation.
    Jaruratanasirikul S; Vattanavanit V; Samaeng M; Nawakitrangsan M; Sriwiriyajan S
    Clin Drug Investig; 2019 Aug; 39(8):787-798. PubMed ID: 31124013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation.
    Fratoni AJ; Kois AK; Gluck JA; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2024 May; 79(5):1118-1125. PubMed ID: 38517465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.
    Couffignal C; Pajot O; Laouénan C; Burdet C; Foucrier A; Wolff M; Armand-Lefevre L; Mentré F; Massias L
    Br J Clin Pharmacol; 2014 Nov; 78(5):1022-34. PubMed ID: 24903189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is continuous infusion of imipenem always the best choice?
    Suchánková H; Lipš M; Urbánek K; Neely MN; Strojil J
    Int J Antimicrob Agents; 2017 Mar; 49(3):348-354. PubMed ID: 28189734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
    Sakka SG; Glauner AK; Bulitta JB; Kinzig-Schippers M; Pfister W; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3304-10. PubMed ID: 17620371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions.
    Lipš M; Siller M; Strojil J; Urbánek K; Balík M; Suchánková H
    Int J Antimicrob Agents; 2014 Oct; 44(4):358-62. PubMed ID: 25216543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia.
    Jaruratanasirikul S; Wongpoowarak W; Jullangkoon M; Samaeng M
    J Pharmacol Sci; 2015 Feb; 127(2):164-9. PubMed ID: 25727953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imipenem Population Pharmacokinetics: Therapeutic Drug Monitoring Data Collected in Critically Ill Patients with or without Extracorporeal Membrane Oxygenation.
    Chen W; Zhang D; Lian W; Wang X; Du W; Zhang Z; Guo D; Zhang X; Zhan Q; Li P
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii.
    Jaruratanasirikul S; Nitchot W; Wongpoowarak W; Samaeng M; Nawakitrangsan M
    Eur J Pharm Sci; 2019 Aug; 136():104940. PubMed ID: 31132402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of daptomycin in critically ill patients receiving extracorporeal membrane oxygenation.
    Zhang LC; Li QY; Zhang YQ; Shan TC; Li Y; Li YH; Han H; Qin WD; Guo HP; Zhao W; Tang BH; Chen XM
    J Antimicrob Chemother; 2024 Jul; 79(7):1697-1705. PubMed ID: 38814793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
    O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data.
    Yoshizawa K; Ikawa K; Ikeda K; Kumon H; Ohge H; Morikawa N
    Int J Antimicrob Agents; 2012 Nov; 40(5):427-33. PubMed ID: 22877766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose Optimization of Cefpirome Based on Population Pharmacokinetics and Target Attainment during Extracorporeal Membrane Oxygenation.
    Kang S; Jang JY; Hahn J; Kim D; Lee JY; Min KL; Yang S; Wi J; Chang MJ
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and Pharmacodynamic Analysis of Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Imipenem.
    Li Z; Bai J; Wen A; Shen S; Duan M; Li X
    Clin Ther; 2020 Aug; 42(8):1564-1577.e8. PubMed ID: 32741646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults.
    Kispal B; Walker SAN
    Eur J Clin Pharmacol; 2021 Feb; 77(2):197-205. PubMed ID: 32975650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.